# SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)

> **NCT07725705** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 44 (estimated)

## Conditions studied

- PTCL
- First Line Treatment

## Interventions

- **DRUG:** SHR2554 combined with Liposomal Mitoxantrone

## Key facts

- **NCT ID:** NCT07725705
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725705, "SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07725705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*